TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT02129751: A Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder

Sponsor: Bausch Health Americas, Inc. · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 246 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,499,200

Rescue Site Savings

+$5,604,160

Unlock Full NCT02129751 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02129751 Rescue Dossier →